Organoid-driven nanomedicine platform development.

Abstract

The integration of organoid models with nanomedicine delivery systems offers a novel approach to drug discovery and personalized medicine by enabling more accurate, efficient, and physiologically relevant evaluation of therapeutic efficacy. Organoids, three-dimensional (3D) cell structures cultivated in vitro from stem cells or adult stem cells, mimic the architecture and functionality of human tissues, providing a more accurate platform for disease modeling, drug screening, and toxicity testing compared to traditional two-dimensional (2D) cell cultures. Meanwhile, nanomedicine delivery systems have garnered significant attention in pharmaceutical research due to their ability to enhance drug stability, control drug release, and target specific tissues. The combination of organoid technology and nanomedicine platforms holds immense potential to advance drug development and improve individualized therapeutic strategies. This review aims to summarize recent advancements in organoid-driven nanomedicine platforms, explore their applications in drug screening, toxicological evaluation, and personalized medicine, and address the challenges and future directions in this emerging field.